State of Wyoming Raises Position in Enfusion, Inc. (NYSE:ENFN)

State of Wyoming increased its position in Enfusion, Inc. (NYSE:ENFN) by 52.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 76,814 shares of the company’s stock after buying an additional 26,525 shares during the period. State of Wyoming’s holdings in Enfusion were worth $791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Enfusion during the 4th quarter valued at about $75,000. Millennium Management LLC acquired a new stake in shares of Enfusion during the 4th quarter valued at about $114,000. Dark Forest Capital Management LP acquired a new stake in shares of Enfusion during the 4th quarter valued at about $128,000. Man Group plc acquired a new stake in shares of Enfusion during the 4th quarter valued at about $131,000. Finally, Tower Research Capital LLC TRC grew its position in shares of Enfusion by 58.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 13,227 shares of the company’s stock valued at $136,000 after acquiring an additional 4,889 shares during the period. Hedge funds and other institutional investors own 81.05% of the company’s stock.

Enfusion Stock Up 0.5%

NYSE:ENFN opened at $10.85 on Monday. Enfusion, Inc. has a 52 week low of $7.83 and a 52 week high of $11.80. The stock has a market capitalization of $1.40 billion, a PE ratio of 271.29, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. The stock’s 50-day moving average price is $10.91 and its 200-day moving average price is $10.69.

Enfusion (NYSE:ENFN) last posted its earnings results on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a net margin of 1.70% and a return on equity of 6.67%. The business had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Sell-side analysts expect that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Oleg Movchan sold 2,790 shares of Enfusion stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the sale, the chief executive officer now directly owns 643,299 shares in the company, valued at approximately $7,385,072.52. The trade was a 0.43% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Neal Pawar sold 14,560 shares of Enfusion stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $165,692.80. Following the completion of the sale, the chief operating officer now owns 1,217,067 shares in the company, valued at approximately $13,850,222.46. The trade was a 1.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,223 shares of company stock worth $754,778. Insiders own 36.44% of the company’s stock.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.